Fibroblast activating protein (FAP) is a membrane bound serine protease up-regulated in activated fibroblasts. These are essential for tissue remodeling in wound healing, chronic inflammation as well as in carcinoma associated fibroblasts (CAF) in several types of cancer1258911. Subject of recent developments are new⁶⁸Ga-labelled PET tracers that operate as FAP-specific enzyme inhibitors (FAPi). The inhibitor is a small molecule based on a 4.4-difluoroproline-quinoline motif with a carbonitrile ...

A schwannoma is a benign mesenchymal tumor, which originates from Schwann cells in the nerve sheath. Most of the schwannomas are located in the cranial or spinal canal cavity, while some may be located in the hepatic hilar region though this is extremely rare. Herein, we present a case of an older woman with two schwannomas in the hepatic hilar region, who then had preoperative multimodal imaging, in which¹⁸F-FDG PET/CT scans showed a markedly increased¹⁸F-FDG uptake, mimicking that of malignant...

Background  In somatostatin receptor (SSTR) expressing progressive meningioma, peptide receptor radionuclide therapy (PRRT) has shown effect in small clinical series. However, standardized treatment and response assessment protocols are lacking. We present our experience on PPRT with¹⁷⁷Lu-DOTATATE in progressive meningioma with a special emphasis on state-of-the-art response assessment.

Methods  Retrospective analysis on PRRT with¹⁷⁷Lu-DOTATATE from 2015 to 2019. Pre- and post-therapy imaging was p...

Aim  The objective of this study was to assess the impact of implementing FDG-PET imaging in treatment algorithms for differentiated thyroid cancer with suspected recurrence. Primary end points were overall, event-free and disease-specific survival. Secondary end points were therapies, disease control and the sensitivity and specificity of PET imaging.

Methods  194 patients with DTC treated at our center from 1996 to 2014 following thyroidectomy and routine¹³¹I ablation with no remaining¹³¹I uptake...

Objective  Patients with advanced prostate cancer are suitable candidates for [¹⁷⁷Lu]PSMA-617 therapy. Integrated SPECT/CT systems have the potential to improve the accuracy of patient-specific tumor dosimetry. We present a novel patient-specific Monte Carlo based voxel-wise dosimetry approach to determine organ and total tumor doses (TTD).

Methods  13 patients with histologically confirmed metastasized castration-resistant prostate cancer were treated with a total of 18 cycles of [¹⁷⁷Lu]PSMA-617 t...